Leidos (LDOS) Expected to Announce Quarterly Earnings on Tuesday

Leidos (NYSE:LDOS) is anticipated to post its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $2.54 per share and revenue of $4.3143 billion for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 8:00 AM ET.

Leidos Stock Up 0.8%

LDOS stock opened at $194.58 on Tuesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.62 and a quick ratio of 1.50. The firm has a market cap of $24.88 billion, a PE ratio of 18.15, a P/E/G ratio of 1.35 and a beta of 0.59. Leidos has a 12 month low of $123.62 and a 12 month high of $205.77. The firm has a 50 day simple moving average of $188.96 and a 200 day simple moving average of $186.06.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LDOS. Bank of America increased their price objective on Leidos from $200.00 to $235.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Citigroup boosted their price target on Leidos from $218.00 to $232.00 and gave the company a “buy” rating in a research note on Tuesday, January 13th. Wall Street Zen upgraded shares of Leidos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of Leidos in a research note on Monday, December 29th. Finally, Truist Financial reissued a “buy” rating and issued a $220.00 price target (up previously from $200.00) on shares of Leidos in a research report on Tuesday, November 4th. Nine analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $213.09.

Insiders Place Their Bets

In related news, insider Elizabeth A. Porter sold 3,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $192.21, for a total transaction of $576,630.00. Following the sale, the insider directly owned 38,575 shares in the company, valued at $7,414,500.75. This represents a 7.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.69% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Moneta Group Investment Advisors LLC acquired a new position in Leidos in the third quarter valued at about $228,000. Hilltop Holdings Inc. bought a new stake in shares of Leidos in the 3rd quarter valued at about $237,000. GeoWealth Management LLC increased its stake in shares of Leidos by 27.1% in the 3rd quarter. GeoWealth Management LLC now owns 1,181 shares of the aerospace company’s stock valued at $223,000 after acquiring an additional 252 shares during the last quarter. Certuity LLC acquired a new stake in shares of Leidos in the 3rd quarter valued at approximately $226,000. Finally, Evergreen Capital Management LLC bought a new position in Leidos during the 2nd quarter worth approximately $209,000. 76.12% of the stock is currently owned by institutional investors.

Leidos Company Profile

Leidos is an American technology and engineering company that provides services and solutions to government and commercial customers, with a strong focus on national security, defense, intelligence, and civil government markets. The company delivers systems integration, engineering, cybersecurity, software development, data analytics, cloud migration and managed IT services, as well as mission support for complex programs. Leidos’ work spans areas such as C4ISR (command, control, communications, computers, intelligence, surveillance and reconnaissance), secure communications, sensors and systems engineering, and health IT solutions for public-sector healthcare programs.

Leidos traces its corporate roots to Science Applications International Corporation (SAIC) and emerged as an independent, publicly traded company following a corporate separation in 2013.